Does Reimbursement Influence Chemotherapy Treatment For Cancer Patients?
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Before the Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003, Medicare reimbursed physicians for chemotherapy drugs at rates that greatly exceeded physicians' costs for those drugs. We examined the effect of physician reimbursement on chemotherapy treatment of Medicare beneficiaries older than age sixty-five with metastatic lung, breast, colorectal, or other gastrointestinal cancers between 1995 and 1998 (9,357 patients). A physician's decision to administer chemotherapy to metastatic cancer patients was not measurably affected by higher reimbursement. Providers who were more generously reimbursed, however, prescribed more-costly chemotherapy regimens to metastatic breast, colorectal, and lung cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452
Cited by
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
Aggressiveness of Cancer Care Near the End of Life: Is It a Quality-of-Care Issue?
Earle, C. C., Landrum, M. B., Souza, J. M., Neville, B. A., Weeks, J. C., & Ayanian, J. Z. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8253 · Cited by 949
Self-citationPricing in the Market for Anticancer Drugs
Howard, D. H., Bach, P. B., Berndt, E. R., & Conti, R. M. (2015) · Journal of Economic Perspectives · doi:10.1257/jep.29.1.139 · Cited by 444
NCCN Task Force Report: Oral Chemotherapy
Weingart, S. N., Brown, E., Bach, P. B., Eng, K., Johnson, S. A., Kuzel, T. M., Langbaum, T. S., Leedy, R. D., Muller, R. J., Newcomer, L. N., et al. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.2003 · Cited by 435
Technology Growth and Expenditure Growth in Health Care
Chandra, A., & Skinner, J. (2012) · Journal of Economic Literature · doi:10.1257/jel.50.3.645 · Cited by 412
Bending the Cost Curve in Cancer Care
Smith, T. J., & Hillner, B. E. (2011) · New England Journal of Medicine · doi:10.1056/nejmsb1013826 · Cited by 391
Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
Bach, P. B. (2009) · New England Journal of Medicine · doi:10.1056/nejmhpr0807774 · Cited by 390
Cost of Cancer Care: Issues and Implications
Meropol, N. J., & Schulman, K. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6081 · Cited by 351
Balboni, T., Balboni, M., Paulk, M. E., Phelps, A., Wright, A., Peteet, J., Block, S., Lathan, C., VanderWeele, T., & Prigerson, H. (2011) · Cancer · doi:10.1002/cncr.26221 · Cited by 330
“Receipt of chemotherapy in the last week of life was estimated at $821 (25% of estimated $3281 per 4 weeks).(31)”
BackgroundPhysician Beliefs and Patient Preferences: A New Look at Regional Variation in Health Care Spending
Cutler, D., Skinner, J. S., Stern, A. D., & Wennberg, D. (2019) · American Economic Journal: Economic Policy · doi:10.1257/pol.20150421 · Cited by 313
The Role of Chemotherapy at the End of Life: “When Is Enough, Enough?”
Harrington, S. E., & Smith, T. J. (2008) · JAMA · doi:10.1001/jama.299.22.2667 · Cited by 280
The High Cost of Cancer Drugs and What We Can Do About It
Siddiqui, M., & Rajkumar, S. V. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.07.007 · Cited by 255
Quality of Life and Cost of Care at the End of Life: The Role of Advance Directives
Garrido, M. M., Balboni, T. A., Maciejewski, P. K., Bao, Y., & Prigerson, H. G. (2015) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2014.09.015 · Cited by 126
Barriers to the Use of Personalized Medicine in Breast Cancer
Weldon, C. B., Trosman, J. R., Gradishar, W. J., Benson, A. B., & Schink, J. C. (2012) · Journal of Oncology Practice · doi:10.1200/jop.2011.000448 · Cited by 76
Metadata
- Authors
- Jacobson, M., O’Malley, A. J., Earle, C. C., Pakes, J., Gaccione, P., & Newhouse, J. P.
- Venue
- Health Affairs
- Publisher
- Health Affairs Publishing, LLC
- Published
- 2006-03
- Volume
- 25
- Issue
- 2
- Pages
- 437-443
- ISSN
- 0278-2715 (ISSN-L)
- 1544-5208
- OpenAlex
- W2062260935
- Cited by
- 136
- References
- 1
- FWCI
- 15.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.